Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

H. Sehn, Laurie; Hertzberg, Mark; Opat, Stephen; F. Herrera, Alex; Assouline, Sarit; R. Flowers, Christopher; Min Kim, Tae; McMillan, Andrew; Özcan, Muhıt; Safar, Violaine; Salles, Gilles; Ku, Grace; Hirata, Jamie; Meng Chang, Yi; Musick, Lisa; J. Matasar, Matthew

doi:10.1182/bloodadvances.2021005794

Public

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data

Published in Blood Advances • Nov 8, 2021

Authors:

Laurie H. Sehn

Mark Hertzberg

Stephen Opat

Abstract

Polatuzumab vedotin plus bendamustine and rituximab (pola + BR) received regulatory approvals for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) based on primary results from the randomized arms of the GO29365 study. After the randomized phase, 106 additional patients received pola + ...

Subject

Medicine

Bendamustine

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!